The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | Pre/post allo-SCT checkpoint inhibitors: a double-edged sword
The double-edged sword of checkpoint inhibitors used before or after allogeneic hematopoietic stem cell transplant is discussed here by Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX. This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
